Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
ProMIS Neurosciences (PMN) appointed Slanix Paul Alex, Pharm.D., to its Board of Directors effective October 22, 2025. The Board determined he is independent under Nasdaq listing standards, and committee compositions remain unchanged. Dr. Alex is President and Portfolio Manager for the Public Equity strategy at Ally Bridge Group, with prior investing and research roles at Tri Locum Partners, Consonance Capital, RBC, and Credit Suisse. He holds a Pharm.D. from St. John’s University and is a licensed pharmacist.
Under the company’s non-employee director compensation policy, Dr. Alex received an option to purchase 40,000 common shares, vesting 25% at grant with the balance vesting ratably over 36 months, and an annual cash fee of $40,000. Beginning with the 2026 annual meeting, he will be eligible for an additional option to purchase 20,000 shares each year, vesting on the earlier of the one-year anniversary or the next annual meeting. Per Ally Bridge Group’s governance policy, his equity awards and cash compensation are attributed to Ally Bridge MedAlpha Master Fund L.P.
Insider purchase recorded by ProMIS Neurosciences (PMN). On 10/03/2025 Max A. Milbury, an officer serving as Principal Accounting Officer, acquired 30,392 common shares at $0.4912 per share. After the purchase he beneficially owned 45,389 shares. The Form 4 filed and signed on 10/06/2025 reports the transaction as a purchase by one reporting person and shows the ownership as direct. The filing supplies transaction price, share count, role of the reporting person, and post-transaction holdings.
ProMIS Neurosciences Inc. is seeking shareholder approval at a virtual Special Meeting for a proposed share consolidation (reverse split). Holders of record as of September 26, 2025 may attend online via a unique link after registration; materials are available at www.proxyvote.com and www.sedarplus.ca. Approval of Proposal No. 1 requires 66 2/3% of votes cast, and the Board unanimously recommends a vote FOR. The statement warns the consolidation will reduce the number of outstanding shares and the stated capital attributed to Common Shares, and will retroactively increase per‑share net loss for prior periods. The proxy explains voting mechanics, broker voting rules, and basic U.S. and Canadian tax considerations for shareholders.
Jeremy M. Sclar 2012 Irrevocable Family Trust reported a series of warrant exercises and a warrant purchase in ProMIS Neurosciences (PMN). On 07/25/2025 the JS Trust exercised three tranches of purchase warrants, each for 697,674 common shares, for a total of 2,093,022 shares, at an agreed exercise price of $0.83518 per share instead of the original scheduled prices of $2.02 and $2.50. Following those exercises the Trust reported beneficial ownership totals rising in steps to 3,710,459 shares. On 07/29/2025 the Trust acquired a new warrant to purchase 3,139,533 common shares at $1.25 per share (the warrant was purchased at $0.1875 per underlying share and expires in five years).
Jeremy M. Sclar 2012 Irrevocable Family Trust filed an Initial Statement of Beneficial Ownership reporting direct ownership of 1,617,437 common shares of ProMIS Neurosciences, Inc. (PMN) and multiple warrants convertible into additional common shares. Reported derivative holdings include 26,217 warrants (exercise $7.50, exp. 04/11/2028), 664,894 warrants (exercise $1.75, exp. 02/24/2029), and three tranches of purchase warrants from a July 31, 2024 private placement totaling 2,093,022 underlying shares across Tranche A, B and C (exercise prices of $2.02 for A and B, $2.50 for C; various exercisability and expiry conditions). The Form 3 identifies the reporting person as a Director and the filing is made by one reporting person.
ProMIS Neurosciences Inc. updated the employment terms of its Chief Scientific Officer, Dr. Neil Cashman, through an Amended and Restated Employment Agreement effective September 26, 2025. Dr. Cashman will remain on the board and continue in his role as Chief Scientific Officer.
The amended agreement sets an annual base salary of $500,000 CAD and an annual discretionary bonus targeted at 35% of base salary. Dr. Cashman received an option to purchase 165,000 common shares at Fair Market Value on the grant date, vesting 25% after one year and the balance in equal monthly installments over thirty-six months.
He is entitled to 9 months of salary and continued benefits if terminated without cause, and to 9 months of salary, accelerated vesting of time-based equity awards, and continued benefits in connection with a change in control. The company states there are no family relationships or related-party transactions requiring disclosure.
Neil K. Warma, Chief Executive Officer and Director of ProMIS Neurosciences Inc. (PMN), reported a Section 16 transaction on Form 4 showing the acquisition of derivative securities on 09/22/2025. The filing records an award of 600,000 stock options with an exercise price of $0.45 that expire on 09/22/2035. Following the reported transaction, Mr. Warma beneficially owns 600,000 options directly. The options vest with 25% vesting on September 1, 2026 and the remainder vesting ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Insider option grant reported for ProMIS Neurosciences (PMN). Max A. Milbury, listed as Principal Accounting Officer, was granted an option to purchase 60,000 common shares at an exercise price of $0.45 per share on 09/22/2025. The option has an expiration date of 09/22/2035. Vesting: 25% vests on 09/01/2026, with the remainder vesting ratably over the next 36 months. The filing was signed 09/24/2025 and is a single-person Form 4.
ProMIS Neurosciences (PMN) reported an insider option grant to Neil Cashman, who serves as a director and Chief Scientific Officer. The report shows an option to purchase 165,000 common shares with a $0.45 exercise price, granted with a transaction date of 09/22/2025. The option becomes exercisable on 09/22/2025 and expires on 09/22/2035. Vesting is specified: 25% vests on September 1, 2026 and the remainder vests ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact for Mr. Cashman on 09/24/2025. The filing reflects a non-derivative underlying position of 165,000 common shares after the reported transaction.
ProMIS Neurosciences (PMN) reported an insider option grant to Neil Cashman, who serves as a director and Chief Scientific Officer. The report shows an option to purchase 165,000 common shares with a $0.45 exercise price, granted with a transaction date of 09/22/2025. The option becomes exercisable on 09/22/2025 and expires on 09/22/2035. Vesting is specified: 25% vests on September 1, 2026 and the remainder vests ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact for Mr. Cashman on 09/24/2025. The filing reflects a non-derivative underlying position of 165,000 common shares after the reported transaction.
ProMIS Neurosciences reported an insider equity award: Chief Development Officer Johanne Kaplan was granted an option to buy 165,000 common shares at a $0.45 exercise price. The option was granted on 09/22/2025, becomes exercisable beginning 09/22/2025, and expires on 09/22/2035. Under the disclosed vesting schedule, 25% of the option vests on 09/01/2026 and the remaining portion vests ratably over the following 36 months. The Form 4 was signed on behalf of Ms. Kaplan on 09/24/2025 by an attorney-in-fact.